Novel Molecular Determinants of Response or Resistance to Immune Checkpoint Inhibitor Therapies in Melanoma.

Front Immunol · 2021 · PMC8787219 · PMID 35087523

Europe PMC DOI

hedged sentence

0.0940

closest p · 1.9× alpha

0.0940

boldest claim

The sentences

did not reach statistical significancep = 0.094so close (0.05 < p ≤ 0.1)

In the anti-PD-1/PD-L1 therapy, a trend of better prognosis was observed in COL3A1 -mutated patients, although it did not reach statistical significance (log-rank test p = 0.094; Figure S6B ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.